

YOUR GUIDE TO

REGEN-COV™ 
(casirivimab with imdevimab)

REGENERON

HERE'S WHAT YOU NEED TO KNOW ABOUT REGEN-COV™ (casirivimab with imdevimab)

If you've recently tested positive for coronavirus disease 2019 (COVID-19), a new treatment option called REGEN-COV (REE-jen-cove) may be right for you.

In this guide, you'll learn about REGEN-COV, including what it is, who it is for, its possible benefits, and important safety information. REGEN-COV is investigational, which means it's a new drug that is still being studied, so there's a lot that experts still don't know about it. And remember, it's always important to discuss possible treatment options with your healthcare provider.

What is REGEN-COV and how does it work?

When you get infected with a virus, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, your immune system creates antibodies to fight it off. It takes time for your body to make these antibodies, which allows the infection to get worse and make you sicker.

REGEN-COV contains two monoclonal antibodies that neutralize SARS-CoV-2 to help patients fight and recover from COVID-19. Being treated with REGEN-COV antibodies as soon as you are diagnosed with COVID-19 may limit the amount of virus that develops in your body, which may help you recover from the infection.

REGEN-COV is a combination monoclonal antibody treatment for COVID-19. "Combination" means that it contains two different monoclonal antibodies, casirivimab (CASS-uh-RIV-uh-mab) and imdevimab (im-DEV-uh-mab) that work together to help fight the infection. REGEN-COV is a one-time intravenous infusion—so no need for multiple doses.

Know your options. If you received a positive COVID-19 test, talk to your healthcare provider right away about REGEN-COV.

Important notes about REGEN-COV

REGEN-COV (casirivimab with imdevimab) is an investigational medicine used to treat mild to moderate symptoms of COVID-19 in non-hospitalized adults and adolescents (12 years of age and older who weigh at least 88 pounds [40 kg]), and who are at high risk for developing severe COVID-19 symptoms or the need for hospitalization. REGEN-COV is investigational because it is still being studied. There is limited information known about the safety and effectiveness of using REGEN-COV to treat people with COVID-19.

- REGEN-COV has not been approved, but has been authorized for emergency use by FDA
- This use is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner
- For additional information on REGEN-COV, please see the [FDA Letter of Authorization](#), [Fact Sheet for Healthcare Providers](#), and [Fact Sheet for Patients, Parents and Caregivers](#)


**PLEASE SEE IMPORTANT SAFETY
INFORMATION THROUGHOUT THIS GUIDE.**

REGENERON

WHAT IS COVID-19?

COVID-19 is caused by a virus called a coronavirus. People can get COVID-19 through contact with another person who has the virus.

COVID-19 illnesses have ranged from very mild (including some with no reported symptoms) to severe, including illness resulting in death. While information so far suggests that most COVID-19 illness is mild, serious illness can occur and may cause some of your other medical conditions to worsen. People of all ages with severe, long-lasting (chronic) medical conditions like heart disease, lung disease, or diabetes, for example, seem to be at higher risk of being hospitalized for COVID-19.



What are the symptoms?

Each person may experience different symptoms. The most commonly reported symptoms of COVID-19, which may appear 2 to 14 days after exposure, include:

- Fever
- Cough
- Shortness of breath
- Fatigue
- Muscle or body aches
- Headache
- New loss of taste or smell
- Sore throat
- Congestion or runny nose
- Nausea or vomiting
- Diarrhea

This list does not include all possible symptoms. For more information and updates, please visit the CDC website at <https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html>.

If you tested positive for COVID-19, talk to your healthcare provider right away to see if REGEN-COV™ (casirivimab with imdevimab) is right for you.

PLEASE SEE IMPORTANT SAFETY
INFORMATION THROUGHOUT THIS GUIDE.

REGENERON

WHO IS ELIGIBLE FOR REGEN-COV™ (casirivimab with imdevimab)?

REGEN-COV is an investigational medicine used to treat mild to moderate symptoms of COVID-19 in non-hospitalized persons who are:

- at least 12 years old AND
- at least 88 pounds (40 kg) AND
- at high risk of developing severe COVID-19 symptoms or the need for hospitalization



Am I at high risk?:

You should speak to your healthcare provider about your risk factors. These are the risk factors that might make you eligible for treatment with REGEN-COV:

- Have a body mass index (BMI) ≥ 35
- Have chronic kidney disease
- Have diabetes
- Have immunosuppressive disease
- Are currently receiving immunosuppressive treatment
- Are ≥ 65 years of age
- Are ≥ 55 years of age AND have
 - cardiovascular disease, OR
 - hypertension, OR
 - chronic obstructive pulmonary disease/ other chronic respiratory disease
- Are 12-17 years of age AND have
 - BMI ≥ 85 th percentile for their age and gender based on CDC growth charts, https://www.cdc.gov/growthcharts/clinical_charts.htm, OR
 - sickle cell disease, OR
 - congenital or acquired heart disease, OR
 - neurodevelopmental disorders, for example, cerebral palsy, OR
 - a medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19), OR
 - asthma, reactive airway or other chronic respiratory disease that requires daily medication for control

**PLEASE SEE IMPORTANT SAFETY
INFORMATION THROUGHOUT THIS GUIDE.**

REGENERON

WHAT ARE THE IMPORTANT POSSIBLE SIDE EFFECTS?

Warnings and important possible side effects of REGEN-COV™ (casirivimab with imdevimab)

Allergic reactions: Allergic reactions can happen during and after infusion with REGEN-COV. Tell your healthcare provider right away if you get any of the following signs and symptoms of allergic reactions:

- Fever
- Shortness of breath
- Weakness
- Swelling of your lips, face, or throat
- Muscle aches
- Chills
- Low or high blood pressure
- Confusion
- Dizziness
- Nausea
- Rapid or slow heart rate
- Feeling tired
- Rash, including hives and itching
- Sweating
- Headache
- Chest discomfort or pain
- Wheezing

These reactions may be severe or life threatening.

Worsening symptoms after treatment: You may experience new or worsening symptoms after infusion, including fever, difficulty breathing, rapid or slow heart rate, tiredness, weakness, or confusion. If these occur, contact your healthcare provider or seek immediate medical attention as some of these events have required hospitalization. It is unknown if these events are related to treatment or are due to the progression of COVID-19.

The side effects of getting any medicine by vein may include brief pain, bleeding, bruising of the skin, soreness, swelling, and possible infection at the infusion site.

These are not all the possible side effects of REGEN-COV. Not a lot of people have been given REGEN-COV. Serious and unexpected side effects may happen. REGEN-COV is still being studied, so it is possible that all of the risks are not known at this time.

It is possible that REGEN-COV could interfere with your body's own ability to fight off a future infection of SARS-CoV-2. Similarly, REGEN-COV may reduce your body's immune response to a vaccine for SARS-CoV-2. Specific studies have not been conducted to address these possible risks. Talk to your healthcare provider if you have any questions.

WHEN SHOULD I SEEK TREATMENT WITH REGEN-COV™ (casirivimab with imdevimab)?


If you have recently tested positive for COVID-19 and are at high risk, it is important to know what to do next, as REGEN-COV should be administered as soon as possible.

If you have tested positive or think you may have COVID-19, talk to your healthcare provider right away to see if REGEN-COV may be right for you.

Getting treated early may help prevent your symptoms from becoming severe and possibly life-threatening.

Before receiving REGEN-COV, tell your healthcare provider about all of your medical conditions, including if you:

- Have any allergies
- Are pregnant or plan to become pregnant
- Are breastfeeding or plan to breastfeed
- Have any serious illnesses
- Are taking any medications (prescriptions, over-the-counter drugs, vitamins, and herbal products)



PLEASE SEE IMPORTANT SAFETY INFORMATION THROUGHOUT THIS GUIDE.

REGENERON


HOW WILL REGEN-COV™ (casirivimab with imdevimab) BE ADMINISTERED?

REGEN-COV consists of two investigational medicines, casirivimab and imdevimab, given together as a single intravenous (IV) infusion (through a vein). The infusion will take 20 to 52 minutes or longer. Your healthcare provider will determine the duration of your infusion.

- You will receive one dose of REGEN-COV by IV infusion
- You will then be monitored for at least 1 hour after the infusion is complete

Where can I receive REGEN-COV?

REGEN-COV is available at certain hospitals, infusion centers, or clinics. Ask your healthcare provider where to go to get your infusion. **If you and your healthcare provider are looking for an infusion center near you, visit <https://locator.infusioncenter.org/>.**



WHAT SHOULD I EXPECT AFTER MY INFUSION?

How soon might I feel better?

In a clinical study, the average time for symptoms to improve was 5 days for those who took REGEN-COV™ (casirivimab with imdevimab) compared to 6 days for those who didn't.

You still may be able to infect others after receiving REGEN-COV, so continue to follow safety guidelines and any additional instructions from your healthcare provider. **Speak to your healthcare provider right away or seek medical attention immediately if your symptoms get worse.**

How much does REGEN-COV cost?

The federal government is working with Regeneron, the manufacturer of REGEN-COV, to make it easier for you to get this important treatment. The federal government purchased the first 1.5 million doses to ensure the medicine is free and accessible to those who need it. However, healthcare facilities may charge fees related to administering the infusion. If you have insurance, it may cover some or all of these fees. You should contact your insurance provider if you have any questions.



Important Safety Information

The side effects of getting any medicine by vein may include brief pain, bleeding, bruising of the skin, soreness, swelling, and possible infection at the infusion site.

These are not all the possible side effects of REGEN-COV. Not a lot of people have been given REGEN-COV. Serious and unexpected side effects may happen. REGEN-COV is still being studied, so it is possible that all of the risks are not known at this time.

**PLEASE SEE IMPORTANT SAFETY
INFORMATION THROUGHOUT THIS GUIDE.**

REGENERON

WHAT ELSE SHOULD I CONSIDER BEFORE RECEIVING REGEN-COV™ (casirivimab with imdevimab)?

What other treatment options are there?

As with REGEN-COV™ (casirivimab with imdevimab), the FDA may allow for the emergency use of other medicines to treat people with COVID-19. Go to <https://www.covid19treatmentguidelines.nih.gov/> for information on other medicines used to treat people with COVID-19.

What if my healthcare provider prescribes REGEN-COV, but I don't want to receive it?

It is your choice to be treated or not to be treated with REGEN-COV. Should you decide not to receive REGEN-COV or stop it at any time, it will not change your current medical care.

What do I need to know about getting both REGEN-COV and a COVID-19 vaccine?

What if I've received a COVID-19 vaccine? Can I still receive REGEN-COV?


Even if you've received a COVID-19 vaccine, you can still receive REGEN-COV if your healthcare provider thinks it is appropriate.

If I've received REGEN-COV, can I still get vaccinated for COVID-19?

Talk to your healthcare provider about when you should receive the COVID-19 vaccine if you have received REGEN-COV.

REGEN-COV is not a vaccine and will not replace receiving the vaccine. REGEN-COV may reduce your body's immune response to a vaccine for SARS-CoV-2. Specific studies have not been conducted to address these possible risks.

Please see [Understanding Your COVID-19 Treatment Options](#) to learn more.



AUTHORIZED USE AND **IMPORTANT SAFETY INFORMATION**

REGEN-COV™ (casirivimab with imdevimab) is an investigational medicine used to treat mild to moderate symptoms of COVID-19 in non-hospitalized adults and adolescents (12 years of age and older who weigh at least 88 pounds [40 kg]), and who are at high risk for developing severe COVID-19 symptoms or the need for hospitalization. REGEN-COV is investigational because it is still being studied. There is limited information known about the safety and effectiveness of using REGEN-COV to treat people with COVID-19.

- REGEN-COV has not been approved, but has been authorized for emergency use by FDA
- This use is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner

Tell your healthcare provider about all of your medical conditions, including if you:

- Have any allergies
- Are pregnant or plan to become pregnant
- Are breastfeeding or plan to breastfeed
- Have any serious illnesses
- Are taking any medications (prescriptions, over-the-counter drugs, vitamins, and herbal products)

Receiving REGEN-COV (casirivimab with imdevimab)

REGEN-COV consists of two investigational medicines, casirivimab and imdevimab, given together as a single intravenous infusion (through a vein). You will receive one dose of REGEN-COV by intravenous infusion. The infusion will take 20 to 52 minutes or longer. Your healthcare provider will determine the duration of your infusion.

AUTHORIZED USE AND **IMPORTANT SAFETY INFORMATION (CONT'D)**

Warnings and important possible side effects of REGEN-COV™ (casirivimab with imdevimab)

- **Allergic reactions:** Allergic reactions can happen during and after infusion with REGEN-COV. Tell your healthcare provider right away if you get any of the following signs and symptoms of allergic reactions: fever, chills, nausea, headache, shortness of breath, low or high blood pressure, rapid or slow heart rate, chest discomfort or pain, weakness, confusion, feeling tired, wheezing, swelling of your lips, face, or throat, rash including hives, itching, muscle aches, dizziness and sweating. These reactions may be severe or life threatening.
- **Worsening symptoms after treatment:** You may experience new or worsening symptoms after infusion, including fever, difficulty breathing, rapid or slow heart rate, tiredness, weakness or confusion. If these occur, contact your healthcare provider or seek immediate medical attention as some of these events have required hospitalization. It is unknown if these events are related to treatment or are due to the progression of COVID-19.

The side effects of getting any medicine by vein may include brief pain, bleeding, bruising of the skin, soreness, swelling, and possible infection at the infusion site.

These are not all the possible side effects of REGEN-COV. Not a lot of people have been given REGEN-COV. Serious and unexpected side effects may happen. REGEN-COV is still being studied, so it is possible that all of the risks are not known at this time.

It is possible that REGEN-COV could interfere with your body's own ability to fight off a future infection of SARS-CoV-2. Similarly, REGEN-COV may reduce your body's immune response to a vaccine for SARS-CoV-2. Specific studies have not been conducted to address these possible risks. Talk to your healthcare provider if you have any questions.

Pregnancy and breastfeeding

There is limited experience treating pregnant women or breastfeeding mothers with REGEN-COV (casirivimab with imdevimab). For a mother and unborn baby, the benefit of receiving REGEN-COV may be greater than the risk from the treatment. If you are pregnant or breastfeeding, discuss your options and specific situation with your healthcare provider.

Please see the [Fact Sheet for Patients, Parents and Caregivers](#) for more information.

REGENERON

© 2021 Regeneron Pharmaceuticals, Inc. All rights reserved.

CAI.21.02.0025 03/2021